Hiring Levels: Senior Scientist, Principal Scientist, or Associate Director
(exact level commensurate with experience)
Company Overview:
Vividion is a next generation biotechnology company based in San Diego that is leveraging its proprietary chemical proteomics platform to conduct proteome-wide footprinting of drug-protein interactions with unprecedented breadth and precision. Our technology allows us to screen, identify and optimize novel drugs that selectively bind virtually any protein, including proteins previously considered “undruggable”. Our pipeline and emerging programs reflect a matured and productive platform capable of delivering first in class drugs utilizing novel mechanisms of action (allosteric inhibitors, protein-protein interaction inhibitors, functional activators, degraders etc.) against undruggable targets in the oncology and immunology space.
We prize scientific excellence, creativity, team players and we are committed to continued innovation. We have worked hard to create a collaborative and dynamic work culture where your ideas and discoveries are valued and will have an impact. We are growing and there are opportunities for mentorship and career progression.
Vividion has been recognized as a Top Workplace by The San Diego Union-Tribune from 2022 to 2025.
Job Summary:
The Project and Regulatory Toxicologist will be expected to use his/her toxicology expertise to guide safety assessment, design and interpret in vitro/in vivo studies to evaluate the safety profiles of our covalently and non-covalently targeted small molecules according to regulatory guidelines. You will work closely with the toxicology function, CROs, and multidisciplinary drug discovery/development teams to progress promising therapeutics to the clinic.
Job details are sourced from the employer's original posting.
Open job postingAbout the company
Vividion Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for cancer and other diseases. They utilize a proprietary chemoproteomic platform to identify and drug previously undruggable targets.